Seoul, South Korea

Mi Young Chol

This inventor holds 1 USPTO granted patent. Top assignee: Industry-University Cooperation Foundation Hanyang University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mi Young Chol. Retrieved from https://idiyas.com/inventor/mi-young-chol

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mi Young Chol and a Patent on Pulmonary Fibrosis

Introduction

Mi Young Chol is an inventor associated with Seoul, South Korea. The available information identifies one patent connected with his work on the diagnosis or treatment of pulmonary fibrosis.

Latest Patents

The listed patent is “Use of M-CSF or G-CSF for Diagnosis or Treatment of Pulmonary Fibrosis.” It concerns the use of M-CSF or G-CSF in approaches to diagnosing or treating pulmonary fibrosis. The provided data lists 1 patent for Mi Young Chol.

Career Highlights

Mi Young Chol is associated with the Industry-University Cooperation Foundation Hanyang University. The listed patent reflects work at the intersection of biomedical research and potential clinical applications.

Collaborations

The provided information names Jae Kyung Myung and Min Jung Kim as coworkers. These names indicate professional connections, though specific roles or contributions to the patent are not provided.

Conclusion

Mi Young Chol’s listed patent focuses on the potential use of M-CSF or G-CSF in pulmonary fibrosis diagnosis or treatment and is associated with the Industry-University Cooperation Foundation Hanyang University.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…